ArticleJournal of thoracic disease2026
Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer ablation treatment is to insert an antenna into the tumor under imaging guidance, resulting in tumor coagulation necrosis through extreme energy changes. It is one of the main local treatments for lung cancer and has become a prominent research area in recent years. The objective of this bibliometric study is to introduce research trends in lung cancer ablation therapy. Methods: Publications on ablative treatment for lung cancer are downloaded from the Web of Science core collection. This analysis includes 919 original English-language articles published between 2002 and 2025. VOSviewer, CiteSpace, and R software are employed to visualize the collected data. Results: In total, 919 original articles were examined. The number of publications is increasing year by year. China ranks first by publication volume. The United States leads in total citations and breadth of international collaboration. The document "Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients", published by Simon in 2007, is the most influential paper (447 citations). This study demonstrates that radiofrequency ablation (RFA) provides favorable tumor control rates and long-term survival outcomes, particularly for lung tumors smaller than 3 cm. RFA is the most prominent research area. Microwave ablation (MWA) and pulmonary nodules have been research hotspots since 2019. Percutaneous cryoablation has gained significant attention since 2023. Conclusions: This bibliometric study provides a comprehensive and quantitative analysis and summary of research in lung cancer ablation, offering researchers insights into the research history, current hotspots, and future directions, aiming at advancing the development of lung cancer ablation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.